KY4 Stock Overview
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for KY4 from our risk checks.
Kyowa Kirin Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥15.40 |
| 52 Week High | JP¥20.40 |
| 52 Week Low | JP¥14.00 |
| Beta | 0.20 |
| 1 Month Change | -5.52% |
| 3 Month Change | 9.22% |
| 1 Year Change | -23.76% |
| 3 Year Change | -38.40% |
| 5 Year Change | -10.38% |
| Change since IPO | 127.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| KY4 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.1% | 1.9% | 1.2% |
| 1Y | -23.8% | -28.2% | 2.0% |
Return vs Industry: KY4 exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: KY4 underperformed the German Market which returned 2% over the past year.
Price Volatility
| KY4 volatility | |
|---|---|
| KY4 Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: KY4 has not had significant price volatility in the past 3 months.
Volatility Over Time: KY4's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 5,974 | Masashi Miyamoto | www.kyowakirin.com |
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics agent.
Kyowa Kirin Co., Ltd. Fundamentals Summary
| KY4 fundamental statistics | |
|---|---|
| Market cap | €8.33b |
| Earnings (TTM) | €480.67m |
| Revenue (TTM) | €2.62b |
17.3x
P/E Ratio3.2x
P/S RatioIs KY4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KY4 income statement (TTM) | |
|---|---|
| Revenue | JP¥442.23b |
| Cost of Revenue | JP¥111.21b |
| Gross Profit | JP¥331.03b |
| Other Expenses | JP¥249.84b |
| Earnings | JP¥81.19b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 151.74 |
| Gross Margin | 74.85% |
| Net Profit Margin | 18.36% |
| Debt/Equity Ratio | 0% |
How did KY4 perform over the long term?
See historical performance and comparisonDividends
2.2%
Current Dividend Yield37%
Payout RatioDoes KY4 pay a reliable dividends?
See KY4 dividend history and benchmarks| Kyowa Kirin dividend dates | |
|---|---|
| Ex Dividend Date | Jun 27 2024 |
| Dividend Pay Date | Sep 02 2024 |
| Days until Ex dividend | 59 days |
| Days until Dividend pay date | 126 days |
Does KY4 pay a reliable dividends?
See KY4 dividend history and benchmarks